our science

healthy neuron and
Our lead program

Eikonizo’s Platform Targets HDAC6

Eikonizo is developing brain-penetrant, small molecule, selective histone deacetylase 6 (HDAC6) inhibitors as disease-modifying therapeutics for neurodegenerative disease, including amyotrophic lateral sclerosis and Alzheimer’s disease.

Therapeutic & Companion Imaging Agent

Our approach combines highly brain-penetrant small molecules with companion PET imaging agents to de-risk and hasten clinical development

Companion HDAC6 PET Tool for Target Engagement

We establish in vivo target engagement early, both pre-clinically and clinically, by utilizing Eikonizo’s proprietary HDAC6 positron emission tomography (PET) imaging tool.

Companion HDAC6 PET Tool for Target Engagement

We have validated our HDAC6 PET tool for human use. Our approach de-risks and hastens clinical development by supporting direct visualization and quantitation of target engagement in the brain of living patients.
Therapeutic Hypothesis

Illustrations of how HDAC6 inhibitor treatment will preserve axonal transport and prevent tau aggregation to stop or slow the progression of ALS and AD

Supporting
Literature

Extensive data from multiple research groups support Eikonizo’s approach for using HDAC6 inhibitors as a disease-modifying therapeutic for neurodegeneration in ALS and AD